Views: 0 Author: Site Editor Publish Time: 2024-04-11 Origin: Site
Atopic dermatitis (AD), a common chronic inflammatory skin disease, is driven by aberrant immune responses and skin barrier dysfunction, with a rising global incidence and a huge unmet need for targeted therapies. The interleukin-25 (IL-25) signaling pathway has been identified as a key regulator of AD pathogenesis, making it a promising target for novel antibody drug development. As a professional preclinical CRO focused on autoimmune and allergic diseases, HKeybio completed a rigorous preclinical efficacy evaluation project for a pharmaceutical customer’s novel anti-IL-25 antibody, providing reliable data support for antibody drug development. This case fully demonstrates HKeybio’s professional capabilities in atopic dermatitis animal modelsand targeted antibody preclinical research.
Atopic dermatitis is a widespread autoimmune-related skin disorder characterized by persistent itching, erythema, skin lesions, and recurrent inflammation, which seriously affects patients’ quality of life. Traditional treatments mostly rely on symptomatic relief, while targeted biological drugs targeting key immune pathways have become a new direction for AD treatment. The IL-25 pathway participates in the activation of type 2 immune responses and the release of inflammatory cytokines, which is closely related to the occurrence and development of AD lesions. Developing specific antibodies against IL-25 is expected to achieve precise intervention of AD pathological processes, bringing new treatment options for clinical patients.
A pharmaceutical company is committed to developing innovative antibody drugs targeting the IL-25 pathway for the clinical treatment of atopic dermatitis. To support the subsequent research and development process of the drug, the customer commissioned HKeybio to conduct a standardized preclinical efficacy evaluation. The core objective of this study is to clarify the efficacy and safety of the nov
el anti-IL-25 antibody in the AD preclinical model, and to compare its therapeutic effect with the clinically approved positive control drug, so as to provide objective and reliable preclinical data for the drug’s research and development progress.
Based on the customer’s research on the IL-25 pathway and AD pathogenesis, HKeybio selected the MC903-induced AD mouse model, which can stably mimic the core pathological characteristics and cytokine expression profiles of human atopic dermatitis, and is highly consistent with the research objectives of targeted pathway intervention.
Crisaborole, a clinical drug with clear efficacy in relieving AD symptoms and regulating immune inflammatory responses, was selected as the positive control to ensure the scientificity and comparability of the experimental results.
The experimental animals were divided into five groups: normal group, vehicle group, positive control group (Crisaborole), anti-IL-25 antibody low-dose group, and anti-IL-25 antibody high-dose group. The treatment cycle was set to 3 weeks, and all drugs were administered topically to simulate the clinical topical administration of AD drugs, ensuring the clinical relevance of the research.
Clinical Assessment: Standardized scoring system to evaluate dermatitis severity, erythema and pruritus
Skin Tissue Analysis: Histological examination of epidermal hyperplasia and inflammatory cell infiltration
Molecular Analysis: Detection of IL-25 downstream signaling pathway and key inflammatory mediators
Pathological Analysis: Evaluation of skin barrier function, keratinocyte proliferation and proinflammatory cytokine expression
This study completed a comprehensive and systematic evaluation from clinical phenotype to molecular mechanism, which provided a solid preclinical foundation for the customer’s anti-IL-25 antibody drug research and development, and also verified the reliability of HKeybio’s preclinical evaluation system for targeted antibodies.
HKeybio, known as the "Autoimmune Disease Model Expert", is a preclinical CRO focusing on autoimmune and allergic diseases, providing full-process in vivo efficacy services. The company has 500+ validated autoimmune and allergic disease animal models, 50+ non-human primate autoimmune and allergic disease models, and the core technical team has more than 20 years of experience in autoimmune disease drug research and development. With 300+ IND filing experiences for autoimmune diseases, HKeybio has passed ISO9001 quality system certification, and has built a full-chain experimental base in Suzhou Industrial Park and two non-human primate experimental bases in Suzhou and Guangxi, which can provide customers with standardized, regulatory-compliant preclinical research services for autoimmune and allergic disease drugs. For more details about our targeted antibody preclinical evaluation services, please visit www.hkeybio.com or contact tech@hkeybio.com.
A: The MC903-induced AD mouse model can stably replicate the core pathological features and cytokine profiles of human atopic dermatitis, which is highly matched with the research purpose of targeting the IL-25 pathway, ensuring the accuracy and clinical relevance of the experimental results.
A: Crisaborole is a clinically approved drug for atopic dermatitis with clear efficacy. It is used as a positive control to verify the validity of the experimental system and compare the therapeutic effect of the novel anti-IL-25 antibody.
A: A multi-dimensional evaluation system was adopted, including clinical symptom scoring, skin tissue histological analysis, molecular detection of IL-25 downstream pathways, and pathological evaluation of skin barrier function.
A: HKeybio has 500+ autoimmune and allergic disease animal models, professional AD model resources, 300+ autoimmune disease IND filing experiences, and a full-chain preclinical research service system.
